HopeAI Unveils AI-Powered Synthetic Data for Faster Cancer Drug Trials

HopeAI has showcased its AI-powered synthetic data technology at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting, announced in a press release. This innovative approach aims to speed up cancer drug trials by generating regulatory-grade evidence without relying on real patient data.

The technology, known as Synthetic Individual Patient Data (SynthIPD), reconstructs individual patient time-to-event and covariate data from published studies with high statistical fidelity. This method allows for rapid trial-level and patient-level surrogacy analyses, significantly reducing the time required for surrogate endpoint validation from years to just weeks.

HopeAI's presentation highlighted the successful application of SynthIPD in multiple myeloma trials, demonstrating a moderate surrogacy relationship between minimal residual disease negativity and progression-free survival. This advancement supports the use of surrogate endpoints as a regulatory measure, potentially accelerating drug approvals and reducing late-stage attrition risks.

The AI-driven approach not only aligns with regulatory expectations but also enhances the efficiency of new drug development, offering a strategic advantage by leveraging Mayo Clinic's real-world data and clinical expertise.